Rochester, NYThis facility was acquired from UCB Pharma in October 2013 to establish a US manufacturing footprint. Deep expertise in the development and manufacture of oral solids, liquids, sustained release, and controlled substances has been enhanced by adding single unit dose capabilities in order to introduce the North American marketplace to the significant benefits offered by such forms.
A team of formulation and analysts experts develop new products for the US market.
The site is FDA inspected and DEA approved. The site has been inspected by Turkish Ministry of Health, MHA (Mexico), ANVISA (Brazil) EMA (EU), FDA (US), MHRA (UK) and Health Canada.